Zolmitriptan Nasal Spray Treats Adolescent Migraine Across Age Groups
Date: 06/09/2017
Zolmitriptan nasal spray may be beneficial in the treatment of migraines in adolescents, according to research presented at the 59th American Headache Society (AHS) Annual Scientific Meeting, held June 8-11, 2017, in Boston, Massachusetts.
Paul Winner, DO, from Albert Einstein College of Medicine and Montefiore Headache Center, Bronx, New York, conducted a study to analyze the effect of patient age on the effectiveness of zolmitriptan nasal spray (ZNS) in adolescent migraine, using the subgroups of younger (between the age of 12 and 14 years) and older (between the age of 15 and 17 years) adolescents.
This article is accurate and up to date at the time of posting, but may not reflect the most recent scientific developments or updates.